Skip to main content
. Author manuscript; available in PMC: 2016 Apr 27.
Published in final edited form as: Nat Commun. 2015 Oct 27;6:8692. doi: 10.1038/ncomms9692

Figure 2. Pharmacokinetic analysis of nanoparticle shows extended microvasculature half-life and heterogeneous tissue accumulation.

Figure 2

(a) Nanoparticle concentrations are monitored (a) and quantified (b) using time-lapse confocal fluorescence microscopy in the dorsal window chamber model. Nanoencapsulation extends the TMV half-life to 55 min, a > 5-fold increase compared to unencapsulated Pt(II) compounds in the same animal model28. Scale bar = 50μm. Thick lines and shading denote means ± S.E.M. (n=6).